Remicade does well in study on inflammation


Washington, D.C. - In a recent 10-week, three-dose phase II trial of inflaximab (Remicade), 87.9 percent of the 250 participants achieved PASI 75, while 58 percent achieved PASI 90 at the 10-week mark.

Related Videos
Related Content
© 2023 MJH Life Sciences

All rights reserved.